Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Prepared by the Czech Society of Cardiology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10129657" target="_blank" >RIV/00179906:_____/12:10129657 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/12:10129657

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0010865012001257" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0010865012001257</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2012.11.008" target="_blank" >10.1016/j.crvasa.2012.11.008</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Prepared by the Czech Society of Cardiology

Popis výsledku v původním jazyce

Guidelines summarise and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition. Since August 2010, when ESC guidelines for the management of atrial fibrillation (AF) were published, European regulatory approvals of several new drugs were announced, reports from major clinical trials of the novel oral anticoagulants revealed, and one antiarrhythmic drug studywas early discontinuated. Therefore, an update of the ESC guidelines was prepared. It is not intended as a comprehensive new guideline. This article is the summary of an update to the 2010 ESC Guidelines.

Název v anglickém jazyce

Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Prepared by the Czech Society of Cardiology

Popis výsledku anglicky

Guidelines summarise and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition. Since August 2010, when ESC guidelines for the management of atrial fibrillation (AF) were published, European regulatory approvals of several new drugs were announced, reports from major clinical trials of the novel oral anticoagulants revealed, and one antiarrhythmic drug studywas early discontinuated. Therefore, an update of the ESC guidelines was prepared. It is not intended as a comprehensive new guideline. This article is the summary of an update to the 2010 ESC Guidelines.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

54

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

11

Strana od-do

"e341"-"e351"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—